Pandipedia entry
Biotech runway is not cash, it is milestone math
Mesoblast said its cash should cover 12 months, including the BLA process for remestemcel-L. Access to existing loan funds depended on receiving first approval and launching within that period. If approval or launch slipped, the company said it might need other financing. Its filing also cited cash covenants and default risk, and identified the uncertainty as a material going-concern issue.
Sorry, Pandi could not find an answer.
Let's look at alternatives:
- Modify the query.
- Start a new thread.
- Remove sources (if manually added).
